Assessment of cytokines, microRNA and patient related outcome measures in conversion disorder/functional neurological disorder (CD/FND): The CANDO clinical feasibility study

Background: Conversion disorder/functional neurological disorder (CD/FND) occurs often in neurological settings and can lead to long-term distress, disability and demand on health care services. Systemic low-grade inflammation might play a role, however, the pathogenic mechanism is still unknown. Ai...

Full description

Bibliographic Details
Main Authors: Christina van der Feltz-Cornelis, Sally Brabyn, Jonathan Ratcliff, Danielle Varley, Victoria Allgar, Simon Gilbody, Chris Clarke, Dimitris Lagos
Format: Article
Language:English
Published: Elsevier 2021-05-01
Series:Brain, Behavior, & Immunity - Health
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666354621000314
id doaj-e4f13d2415cf44ccbd997aa47ce06e06
record_format Article
spelling doaj-e4f13d2415cf44ccbd997aa47ce06e062021-06-10T04:58:10ZengElsevierBrain, Behavior, & Immunity - Health2666-35462021-05-0113100228Assessment of cytokines, microRNA and patient related outcome measures in conversion disorder/functional neurological disorder (CD/FND): The CANDO clinical feasibility studyChristina van der Feltz-Cornelis0Sally BrabynJonathan RatcliffDanielle VarleyVictoria AllgarSimon GilbodyChris ClarkeDimitris LagosCorresponding author.Background: Conversion disorder/functional neurological disorder (CD/FND) occurs often in neurological settings and can lead to long-term distress, disability and demand on health care services. Systemic low-grade inflammation might play a role, however, the pathogenic mechanism is still unknown. Aim: 1) To explore the feasibility to establish and assess a cohort of CD/FND with motor symptoms, involving persons with lived experience (PPI). 2) To generate proof of concept regarding a possible role for cytokines, microRNA, cortisol levels and neurocognitive symptoms in patients with motor CD/FND. Method: Feasibility study. Results: The study showed active involvement of patients despite high clinical illness burden and disability, neurocognitive symptoms, childhood adverse experiences (ACE) and current life events. The study provided valuable knowledge regarding the feasibility of conducting a study in these patients that will inform future study phases. In the sample there were elevated levels of IL6, IL12, IL17A, IFNg, TNFa and VEGF-a, suggesting systemic low-grade inflammation. Also, microRNAs involved in inflammation and vascular inflammation were correlated with TNFa and VEGFa respectively, suggesting proof of concept for an epigenetic mechanism. Owing to the COVID-19 outbreak, the patient sample was limited to 15 patients. Conclusion: It is a novelty that this study is conducted in the clinical setting. This innovative, translational study explores stress-related SLI in CD/FND patients and the feasibility of a larger project aiming to develop new treatments for this vulnerable population. Given the positive findings, there is scope to conduct further research into the mechanism of disease in CD/FND.http://www.sciencedirect.com/science/article/pii/S2666354621000314Conversion disorder/functional neurological disorderFunctional movement disorderCytokinesSystemic low-grade inflammationmicroRNANeurocognitive symptoms
collection DOAJ
language English
format Article
sources DOAJ
author Christina van der Feltz-Cornelis
Sally Brabyn
Jonathan Ratcliff
Danielle Varley
Victoria Allgar
Simon Gilbody
Chris Clarke
Dimitris Lagos
spellingShingle Christina van der Feltz-Cornelis
Sally Brabyn
Jonathan Ratcliff
Danielle Varley
Victoria Allgar
Simon Gilbody
Chris Clarke
Dimitris Lagos
Assessment of cytokines, microRNA and patient related outcome measures in conversion disorder/functional neurological disorder (CD/FND): The CANDO clinical feasibility study
Brain, Behavior, & Immunity - Health
Conversion disorder/functional neurological disorder
Functional movement disorder
Cytokines
Systemic low-grade inflammation
microRNA
Neurocognitive symptoms
author_facet Christina van der Feltz-Cornelis
Sally Brabyn
Jonathan Ratcliff
Danielle Varley
Victoria Allgar
Simon Gilbody
Chris Clarke
Dimitris Lagos
author_sort Christina van der Feltz-Cornelis
title Assessment of cytokines, microRNA and patient related outcome measures in conversion disorder/functional neurological disorder (CD/FND): The CANDO clinical feasibility study
title_short Assessment of cytokines, microRNA and patient related outcome measures in conversion disorder/functional neurological disorder (CD/FND): The CANDO clinical feasibility study
title_full Assessment of cytokines, microRNA and patient related outcome measures in conversion disorder/functional neurological disorder (CD/FND): The CANDO clinical feasibility study
title_fullStr Assessment of cytokines, microRNA and patient related outcome measures in conversion disorder/functional neurological disorder (CD/FND): The CANDO clinical feasibility study
title_full_unstemmed Assessment of cytokines, microRNA and patient related outcome measures in conversion disorder/functional neurological disorder (CD/FND): The CANDO clinical feasibility study
title_sort assessment of cytokines, microrna and patient related outcome measures in conversion disorder/functional neurological disorder (cd/fnd): the cando clinical feasibility study
publisher Elsevier
series Brain, Behavior, & Immunity - Health
issn 2666-3546
publishDate 2021-05-01
description Background: Conversion disorder/functional neurological disorder (CD/FND) occurs often in neurological settings and can lead to long-term distress, disability and demand on health care services. Systemic low-grade inflammation might play a role, however, the pathogenic mechanism is still unknown. Aim: 1) To explore the feasibility to establish and assess a cohort of CD/FND with motor symptoms, involving persons with lived experience (PPI). 2) To generate proof of concept regarding a possible role for cytokines, microRNA, cortisol levels and neurocognitive symptoms in patients with motor CD/FND. Method: Feasibility study. Results: The study showed active involvement of patients despite high clinical illness burden and disability, neurocognitive symptoms, childhood adverse experiences (ACE) and current life events. The study provided valuable knowledge regarding the feasibility of conducting a study in these patients that will inform future study phases. In the sample there were elevated levels of IL6, IL12, IL17A, IFNg, TNFa and VEGF-a, suggesting systemic low-grade inflammation. Also, microRNAs involved in inflammation and vascular inflammation were correlated with TNFa and VEGFa respectively, suggesting proof of concept for an epigenetic mechanism. Owing to the COVID-19 outbreak, the patient sample was limited to 15 patients. Conclusion: It is a novelty that this study is conducted in the clinical setting. This innovative, translational study explores stress-related SLI in CD/FND patients and the feasibility of a larger project aiming to develop new treatments for this vulnerable population. Given the positive findings, there is scope to conduct further research into the mechanism of disease in CD/FND.
topic Conversion disorder/functional neurological disorder
Functional movement disorder
Cytokines
Systemic low-grade inflammation
microRNA
Neurocognitive symptoms
url http://www.sciencedirect.com/science/article/pii/S2666354621000314
work_keys_str_mv AT christinavanderfeltzcornelis assessmentofcytokinesmicrornaandpatientrelatedoutcomemeasuresinconversiondisorderfunctionalneurologicaldisordercdfndthecandoclinicalfeasibilitystudy
AT sallybrabyn assessmentofcytokinesmicrornaandpatientrelatedoutcomemeasuresinconversiondisorderfunctionalneurologicaldisordercdfndthecandoclinicalfeasibilitystudy
AT jonathanratcliff assessmentofcytokinesmicrornaandpatientrelatedoutcomemeasuresinconversiondisorderfunctionalneurologicaldisordercdfndthecandoclinicalfeasibilitystudy
AT daniellevarley assessmentofcytokinesmicrornaandpatientrelatedoutcomemeasuresinconversiondisorderfunctionalneurologicaldisordercdfndthecandoclinicalfeasibilitystudy
AT victoriaallgar assessmentofcytokinesmicrornaandpatientrelatedoutcomemeasuresinconversiondisorderfunctionalneurologicaldisordercdfndthecandoclinicalfeasibilitystudy
AT simongilbody assessmentofcytokinesmicrornaandpatientrelatedoutcomemeasuresinconversiondisorderfunctionalneurologicaldisordercdfndthecandoclinicalfeasibilitystudy
AT chrisclarke assessmentofcytokinesmicrornaandpatientrelatedoutcomemeasuresinconversiondisorderfunctionalneurologicaldisordercdfndthecandoclinicalfeasibilitystudy
AT dimitrislagos assessmentofcytokinesmicrornaandpatientrelatedoutcomemeasuresinconversiondisorderfunctionalneurologicaldisordercdfndthecandoclinicalfeasibilitystudy
_version_ 1721385623878631424